Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mayzent on Microglia in Active SPMS
NCT04925557Phase 3Terminated
- Sponsor
- University at Buffalo
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of siponimod in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by University at Buffalo. Primary endpoint: Change From Baseline in PET Activation at 12 months. Started Nov 2021; status: terminated.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT04925557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925557.